XML 33 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Collaboration, License, Co-Promotion and Other Commercial Agreements (Tables)
6 Months Ended
Jun. 30, 2020
Table Text Blocks  
Schedule of revenue attributable to transactions from collaboration and license arrangements

collaborative arrangements revenue and sale of API primarily attributable to transactions from these arrangements (in thousands):

Three Months Ended

Six Months Ended

June 30, 

June 30, 

Collaborative Arrangements Revenue

2020

    

2019

2020

    

2019

 

Linaclotide Collaboration and License Agreements

AbbVie (North America)

$

86,926

$

75,498

$

158,618

$

140,283

AbbVie (Europe and other)

440

262

1,083

682

AstraZeneca (China, including Hong Kong and Macau)

187

 

519

 

Astellas (Japan)

504

 

983

 

Co-Promotion and Other Agreements:

AbbVie (VIBERZI)(1)

1,239

1,239

Alnylam (GIVLAARI)

1,061

2,006

Other

305

323

659

1,270

Total collaborative arrangements revenue

$

89,423

$

77,322

$

163,868

$

143,474

Sale of API

Linaclotide Agreements:

Astellas (Japan)

$

$

24,893

$

$

27,468

AstraZeneca (China, including Hong Kong and Macau)

9

5,507

Other

3

Total sale of API

$

9

$

24,893

$

5,507

$

27,471

AbbVie  
Table Text Blocks  
Schedule of revenue attributable to transactions from collaboration and license arrangements

The Company recognized collaborative arrangements revenue from the AbbVie collaboration agreement for North America during the three and six months ended June 30, 2020 and 2019 as follows (in thousands):

Three Months Ended

Six Months Ended

June 30, 

June 30, 

    

2020

    

2019

    

2020

    

2019

 

Collaborative arrangements revenue related to sales of LINZESS in the U.S.

$

86,503

$

74,973

$

157,645

$

139,267

Royalty revenue

 

423

 

525

 

973

 

1,016

Total collaborative arrangements revenue

$

86,926

$

75,498

$

158,618

$

140,283

Schedule of amount recorded by the Company for share of net loss related to collaborative arrangement

The following table presents selling, general and administrative costs related to the sale of LINZESS in the U.S. in accordance with the cost-sharing arrangement with AbbVie for the three and six months ended June 30, 2020 and 2019 (in thousands):

Three Months Ended

Six Months Ended

June 30, 

June 30, 

    

2020

    

2019

    

2020

    

2019

 

Selling, general and administrative costs incurred by the Company(1)

$

(3,936)

$

(10,359)

$

(12,610)

$

(20,636)

(1)Excludes an insignificant amount and approximately $0.4 million for the three and six months ended June 30, 2020, respectively, and excludes approximately $0.8 million and approximately $1.3 million for the three and six months ended June 30, 2019, respectively, related to patent prosecution and patent litigation costs recognized in connection with the collaboration agreement with AbbVie for North America.